[go: up one dir, main page]

FR2760193B1 - Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules - Google Patents

Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules

Info

Publication number
FR2760193B1
FR2760193B1 FR9702420A FR9702420A FR2760193B1 FR 2760193 B1 FR2760193 B1 FR 2760193B1 FR 9702420 A FR9702420 A FR 9702420A FR 9702420 A FR9702420 A FR 9702420A FR 2760193 B1 FR2760193 B1 FR 2760193B1
Authority
FR
France
Prior art keywords
lipids
transfection
complexes
cells
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9702420A
Other languages
English (en)
Other versions
FR2760193A1 (fr
Inventor
Rainer Bischoff
Abdessiame Nazid
Yves Cordier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9702420A priority Critical patent/FR2760193B1/fr
Application filed by Transgene SA filed Critical Transgene SA
Priority to EP98912565A priority patent/EP0948360A1/fr
Priority to PCT/FR1998/000389 priority patent/WO1998037916A1/fr
Priority to US09/171,845 priority patent/US6335199B1/en
Priority to CA002252942A priority patent/CA2252942A1/fr
Priority to AU67352/98A priority patent/AU727040B2/en
Priority to JP10537387A priority patent/JP2000510871A/ja
Publication of FR2760193A1 publication Critical patent/FR2760193A1/fr
Application granted granted Critical
Publication of FR2760193B1 publication Critical patent/FR2760193B1/fr
Priority to US10/021,421 priority patent/US20020151070A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9702420A 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules Expired - Fee Related FR2760193B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9702420A FR2760193B1 (fr) 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
PCT/FR1998/000389 WO1998037916A1 (fr) 1997-02-28 1998-02-27 Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US09/171,845 US6335199B1 (en) 1997-02-28 1998-02-27 Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use
CA002252942A CA2252942A1 (fr) 1997-02-28 1998-02-27 Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
EP98912565A EP0948360A1 (fr) 1997-02-28 1998-02-27 Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
AU67352/98A AU727040B2 (en) 1997-02-28 1998-02-27 New lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy
JP10537387A JP2000510871A (ja) 1997-02-28 1998-02-27 少なくとも一種の活性物質特にポリヌクレオチドを標的細胞中へ移送するのに使用できる新規脂質化合物およびこれを含む組成物、ならびに遺伝子治療における使用
US10/021,421 US20020151070A1 (en) 1997-02-28 2001-12-19 Lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9702420A FR2760193B1 (fr) 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules

Publications (2)

Publication Number Publication Date
FR2760193A1 FR2760193A1 (fr) 1998-09-04
FR2760193B1 true FR2760193B1 (fr) 1999-05-28

Family

ID=9504295

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9702420A Expired - Fee Related FR2760193B1 (fr) 1997-02-28 1997-02-28 Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules

Country Status (7)

Country Link
US (2) US6335199B1 (fr)
EP (1) EP0948360A1 (fr)
JP (1) JP2000510871A (fr)
AU (1) AU727040B2 (fr)
CA (1) CA2252942A1 (fr)
FR (1) FR2760193B1 (fr)
WO (1) WO1998037916A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
JP4854853B2 (ja) * 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
ATE312599T1 (de) * 1999-10-01 2005-12-15 Lipoxen Technologies Ltd Impfstoffe zur oralen verwendung die liposomen sowie eine nukleinsäure enthalten
WO2001042200A1 (fr) * 1999-12-10 2001-06-14 Genzyme Corporation Amphiphiles cationiques pour administration intracellulaire de molecules therapeutiques
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
GB0222824D0 (en) * 2002-10-02 2002-11-06 Moredun Res Inst Bacteriophage-mediated immunisation II
JP5777846B2 (ja) 2005-06-15 2015-09-09 マサチューセッツ インスティテュート オブ テクノロジー アミン含有脂質およびその使用
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EA019538B1 (ru) * 2009-04-30 2014-04-30 Бактериефритт Ас Композиция для стерилизации поверхностей
ES2666559T3 (es) 2009-12-01 2018-05-07 Translate Bio, Inc. Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
EP2609135A4 (fr) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
DK3586861T3 (da) 2011-06-08 2022-04-25 Translate Bio Inc Lipidnanopartikelsammensætninger og fremgangsmåder til mrna-indgivelse
EP2859102A4 (fr) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Polynucléotides résistant à la nucléase et leurs utilisations
CA2884870C (fr) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Lipidoides contenant des amines et leurs utilisations
NZ751462A (en) 2013-03-14 2021-07-30 Shire Human Genetic Therapies Cftr mrna compositions and related methods and uses
EP2970955B1 (fr) 2013-03-14 2018-11-14 Translate Bio, Inc. Procédés de purification d'arn messager
WO2014179562A1 (fr) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology Dérivés de 1,3,5-triazinane-2,4,6-trione et leurs utilisations
KR102096796B1 (ko) 2013-10-22 2020-05-27 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 전달을 위한 지질 제형
EP3574923A1 (fr) 2013-10-22 2019-12-04 Translate Bio, Inc. Thérapie d'arnm pour phénylcétonurie
AU2014340092B2 (en) 2013-10-22 2019-09-19 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
EP3636742A1 (fr) 2014-04-25 2020-04-15 Translate Bio, Inc. Procédés de purification d'arn messager
AU2015266764B2 (en) 2014-05-30 2019-11-07 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
JP6599373B2 (ja) 2014-06-24 2019-10-30 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための立体化学的に濃縮した組成物
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016011203A1 (fr) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CA3054062A1 (fr) 2017-02-27 2018-08-30 Translate Bio, Inc. Nouvel arnm cftr a codons optimises
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
AU2018263923B9 (en) 2017-05-02 2024-09-19 Immunomic Therapeutics, Inc. LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens
WO2018213476A1 (fr) 2017-05-16 2018-11-22 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
WO2019222281A1 (fr) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Constructions améliorées de lamp comprenant des allergènes
CA3108544A1 (fr) 2018-08-24 2020-02-27 Translate Bio, Inc. Procedes de purification d'arn messager
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CA3153850A1 (fr) 2019-10-18 2021-04-22 Teri Heiland Constructions ameliorees de lamp comprenant des antigenes du cancer
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP4176087A1 (fr) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Procédé de détermination de la réactivité à un traitement du cancer de la prostate
EP4175721A1 (fr) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
EP4175664A2 (fr) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
CN119233982A (zh) 2022-04-10 2024-12-31 免疫治疗有限公司 包含免疫应答增强基因的双顺反子lamp构建体及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1996040726A1 (fr) 1995-06-07 1996-12-19 Genta Incorporated Nouveaux lipides cationiques a base de carbamate
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
EP0869937A4 (fr) * 1995-07-21 2004-07-21 Promega Biosciences Inc Nouveaux lipides cationiques a base d'amides
DE19607686A1 (de) * 1996-02-29 1997-09-04 Chemicon Lab Gmbh Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung

Also Published As

Publication number Publication date
WO1998037916A1 (fr) 1998-09-03
AU727040B2 (en) 2000-11-30
JP2000510871A (ja) 2000-08-22
EP0948360A1 (fr) 1999-10-13
US20020151070A1 (en) 2002-10-17
CA2252942A1 (fr) 1998-09-03
AU6735298A (en) 1998-09-18
FR2760193A1 (fr) 1998-09-04
US6335199B1 (en) 2002-01-01

Similar Documents

Publication Publication Date Title
FR2760193B1 (fr) Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FI973320L (fi) Kiinteitä aktiiviainetta sisältäviä valmisteita
PL341737A1 (en) Double capsule for administering active substances in multiple-dug therapies
FI972514A0 (fi) Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
PT869126E (pt) Derivados de ditiolano, sua preparacao e seus efeitos terapeuticos
ID26237A (id) Pengantaran zat aktif teraerosolisasi
PL327767A1 (en) Drugs containing known auxiliary substances and an active substance
DE60003938D1 (de) Wirkstoffe in hydrogel-mikroperlen
DE69818443D1 (de) Aktives flüssigkeitslager
DE69821940D1 (de) Landwirtschaftlich aktive inhaltsstoffe enthaltende mikropartikel
PT1069890E (pt) Incorporacao de substancias activas em matrizes veiculares
HU9800075D0 (en) Nucleic acid construct for expressing active substances wich can be activated by proteases, and preparation and use
NO994438L (no) Terapeutisk aktive diarylpropylaminer samt fremstilling og anvendelse derav
DE69710335D1 (de) Wirkstoffabgebende zusatzmittel und diese enthaltende reinigungsmittelstücke
SI1051174T1 (sl) Gastroprotektirane omeprazolne mikrogranule, postopek za pridobivanje le-teh in farmacevtski pripravki
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
DK0927222T3 (da) Termoplastiske polyurethaner indeholdende virksomme stoffer
DE69919490D1 (de) Puder mit fettlöslichem wirkstoff
PT1083790E (pt) Formulacoes de retardacao para substancias activas fitofarmaceuticas
DE69627880D1 (de) Diltiazemhaltige mikrogranulate mit verzögerter wirkstoffabgabe
PL351988A1 (en) Synthetic gene for expressing active retroviral protein in eukaryotes
PT1221845E (pt) Combinacoes de substancias activas com caracteristicas insecticidas e acaricidas
DZ2560A1 (fr) Préparations pharmaceutiques de cilansétrone stabilisées contre la racémisation.
ATE228575T1 (de) Wirkstoffkombinationen
DK0922703T3 (da) Substituerede heterocykliske benzocycloalkener og disses anvendelse som analgetisk virksomme stoffer

Legal Events

Date Code Title Description
ST Notification of lapse